State of New Jersey Common Pension Fund D Acquires 21,810 Shares of AbbVie Inc. $ABBV

State of New Jersey Common Pension Fund D increased its holdings in AbbVie Inc. (NYSE:ABBV) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 617,051 shares of the company’s stock after purchasing an additional 21,810 shares during the period. AbbVie makes up 0.5% of State of New Jersey Common Pension Fund D’s investment portfolio, making the stock its 26th biggest holding. State of New Jersey Common Pension Fund D’s holdings in AbbVie were worth $142,872,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Evolution Wealth Management Inc. bought a new stake in AbbVie during the second quarter worth approximately $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the second quarter worth $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the 2nd quarter worth $36,000. Delos Wealth Advisors LLC acquired a new position in AbbVie in the 2nd quarter valued at $39,000. Finally, Access Investment Management LLC bought a new position in AbbVie in the 2nd quarter worth $44,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Price Performance

ABBV opened at $231.57 on Friday. The company has a market capitalization of $409.28 billion, a P/E ratio of 98.12, a P/E/G ratio of 0.81 and a beta of 0.35. The firm’s fifty day moving average price is $223.56 and its two-hundred day moving average price is $220.85. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ABBV shares. JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.